FDA awarded IPS Heart’s ISX9-CPC rare pediatric drug designation for cardiomyopathies associated with dystrophinopathies. The designation can provide development incentives intended to support clinical testing and development for therapies targeting serious pediatric conditions. The designation strengthens the company’s rare disease pathway planning around a cardiomyopathy niche where patient recruitment and endpoint selection often determine timelines and trial strategy.